

# Association between leukocyte telomere length and serum carotenoid in US adults

Kyoung-Bok Min<sup>1</sup> · Jin-Young Min<sup>2</sup>

Received: 24 April 2015 / Accepted: 3 January 2016  
© Springer-Verlag Berlin Heidelberg 2016

## Abstract

**Purpose** Telomere length is a biomarker for aging. It is known that oxidative stress can accelerate telomere shortening, whereas antioxidants can delay their shortening. Carotenoids as antioxidants are favorably associated with health- and aging-related diseases caused by oxidative stress, but their association with telomere length is less certain. We investigated the association between blood carotenoid levels and leukocyte telomere length in a representative sample of US adults.

**Methods** We analyzed 3660 participants aged 20 years and older in the 1999–2002 National Health and Nutrition Examination Survey. The levels of carotenoids—alpha-carotene, beta-carotene (*trans* + *cis*), beta-cryptoxanthin, combined lutein/zeaxanthin, and *trans*-lycopene—were measured using high-performance liquid chromatography. The leukocyte telomere length (*T/S* ratio) was assayed using the quantitative polymerase chain reaction method.

**Results** A doubling of blood alpha-carotene, beta-carotene (*trans* + *cis*), and beta-cryptoxanthin was associated with approximately 2 % longer telomeres. Compared with the lowest carotenoid quartile of alpha-carotene, beta-carotene (*trans* + *cis*), and beta-cryptoxanthin, telomere length for adults with the highest quartiles was significantly increased by 5–8 %.

**Conclusion** We found that increasing levels of blood carotenoid were significantly associated with longer leukocyte telomeres in US adults. High intake of carotenoid-rich food may play a role in protecting telomeres and regulating telomere length.

**Keywords** Telomere · Oxidative stress · Carotenoid · Antioxidant

## Introduction

Telomeres are nucleoprotein structures at the ends of eukaryotic chromosomes, with a highly conserved repetitive DNA sequence (TTAGGG in human). Telomeres serve multiple functions: They maintain chromosome stability and integrity, regulate cellular proliferation, and prevent chromosome end fusions [1]. In the most somatic cells, telomeres are shortened with each cell division owing to incomplete DNA replication of chromosome ends [2]. In addition, endogenous (i.e., genetics, inflammation, and DNA damage) and environmental (i.e., smoking, alcohol, and life stress) factors are involved in telomere maintenance and regulation [3]. Notably, oxidative stress can accelerate telomere shortening, whereas antioxidants can delay their shortening in human cells [4–6]. Evidence from human studies suggests that dietary intake and blood levels of antioxidants (i.e., vegetable, vitamins C, and vitamin E) are positively associated with telomere length [7, 8].

Carotenoids are naturally occurring yellow, orange, or red pigments found in many fruits and vegetables. Epidemiologic studies have suggested that dietary carotenoid intake or circulating carotenoid serum levels are positively associated with health- and aging-related diseases caused by oxidative stress [9–11]. A recent study examined the

✉ Jin-Young Min  
yaemin00@snu.ac.kr

<sup>1</sup> Department of Environmental Medicine, College of Medicine, Seoul National University, Seoul, Republic of Korea

<sup>2</sup> Institute of Health and Environment, School of Public Health, Seoul National University, 599 Gwanak, Gwanak-ro, Gwanak-gu, Seoul 151-742, Republic of Korea

association between the plasma levels of antioxidative micronutrients and the leukocyte telomere length in 786 elderly adults, who had participated in the Austrian Stroke Prevention Study and reported a significantly protective effect of combined lutein/zeaxanthin on the telomere length [12]. Based on this finding, carotenoid may prevent telomere loss by protecting against oxidative stress-induced DNA damage. However, there is still insufficient evidence regarding the link between carotenoids and telomere length in subjects across a wider span of ages.

In this study, we investigated the association between blood carotenoid levels—provitamin A carotenoids (the carotenes, beta-carotene (*trans* + *cis*), and beta-cryptoxanthin) and non-vitamin A carotenoids (combined lutein/zeaxanthin, and *trans*-lycopene)—and leukocyte telomere length in a representative sample of US adults who participated in the 2001–2002 National Health and Nutrition Examination Survey (NHANES).

## Methods

### Study population

The NHANES, conducted by the Centers for Disease Control and Prevention, is a nationally representative survey of the non-institutionalized US civilian population. The study protocols of the NHANES (1999–2002) were approved by the National Center for Health Statistics Institutional Review Board. Oral and written consent was obtained from all participants.

This study used data collected from 2001 to 2002, in simultaneous measurements of leukocyte telomere length and blood carotenoid levels. Of 5411 participants aged more than 20 years old (the age threshold was set to provide blood samples for DNA purification), we selected 4260 (79 % of those eligible) who agreed to provide DNA samples and specific consent for future genetic research. We then excluded 600 participants for whom there were no data regarding either carotenoids in the blood or at least one of the variables of interest. The result was a final sample size of 3660 participants.

### Measurement of serum carotenoid level

Serum specimens for measurement of carotenoid in the blood were processed, stored, and shipped for the analysis to the Division of Laboratory Sciences at the Centers for Disease Control and Prevention's National Center for Environmental Health. The analytical laboratory followed extensive quality control procedures [13].

Carotenoid levels were measured in serum because serum carotenoid levels are useful biomarkers of the total

dietary intake of vegetables and fruits. The most common types of carotenoids in humans—alpha-carotene, *trans*-beta-carotene, *cis*-beta-carotene, beta-cryptoxanthin, combined lutein/zeaxanthin, and *trans*-lycopene—were assayed in NHANES 2001–2002. Detailed procedures are described elsewhere [13]. High-performance liquid chromatography with photodiode array detection was used to quantify these assays. The median inter-assay coefficients of variation were 8.1 % for alpha-carotene, 5.2 % for *trans*-beta-carotene, 23.3 % for *cis*-beta-carotene, 6.4 % for beta-cryptoxanthin, 11.8 % for combined lutein/zeaxanthin, and 4.6 % for *trans*-lycopene [13].

### Measurement of telomere length

DNA samples were extracted from whole blood using the Puregene (D-50K) kit protocol (Gentra Systems, Inc., Minneapolis, Minnesota) and stored at  $-80^{\circ}\text{C}$ . Telomere length assays were performed in the laboratory of Dr. Elizabeth Blackburn at the University of California, San Francisco. The quantitative polymerase chain reaction method described by Cawthon [14] and Lin et al. [15] was used to measure telomere length, which was determined by the ratio of the telomere repeat copy number (*T*) to the single-copy gene (*S*) copy number (*T/S* ratio) as a control to normalize DNA. The mean telomere length variable was derived by averaging two separate measurements of leukocyte telomere lengths with a maximum variability of 7 %. If the variation was  $>7\%$ , a third assay was performed and the average of the two closest values was used. Details on analytical methods for telomere length have been previously described [16].

### Variables of interest

Questionnaire information included age (20–29, 30–39, 40–49, 50–59, 60–69, 70–79, or  $\geq 80$  years old), sex (male or female), race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, or other), annual household income ( $< \$20,000$  or  $\geq \$20,000$ ), smoking status (current, former, or never), and alcohol consumption (drinker or non-drinker). With regard to disease history, diabetes was defined as having a fasting plasma glucose level of at least 126 mg/dL, a non-fasting plasma glucose level of at least 200 mg/dL, and current insulin use or prior diagnosis of diabetes by a physician. Metabolic variables and other dietary variables, such as the body mass index (BMI), homocysteine, folate, and omega-3 fatty acids, were included as covariates. BMI, calculated by dividing the individual's weight by his or her height squared, was treated as a continuous variable. BMI was categorized into the following four groups: underweight ( $< 18.5\text{ kg/m}^2$ ), normal weight ( $18.5\text{--}22.9\text{ kg/m}^2$ ), overweight ( $23\text{--}24.9\text{ kg/m}^2$ ), and obese ( $\geq 25\text{ kg/m}^2$ ). We grouped the serum homocysteine and folate levels into

**Table 1** Mean leukocyte telomere length (*T/S* ratio) according to participants' characteristics (*N* = 3660)

	<i>N</i> (%)	Mean (95 % CI)	<i>p</i> value
<b>Age (years)</b>			
20–29	687 (18.8)	1.18 (1.16–1.20)	<0.0001
30–39	643 (17.6)	1.10 (1.08–1.12)	
40–49	677 (18.5)	1.06 (1.04–1.08)	
50–59	507 (13.9)	0.99 (0.97–1.01)	
60–69	536 (14.6)	0.93 (0.91–0.94)	
70–79	377 (10.3)	0.88 (0.86–0.90)	
≥80	233 (6.4)	0.84 (0.81–0.86)	
<b>Gender</b>			
Male	1781 (48.7)	1.00 (0.99–1.01)	<0.0001
Female	1879 (51.3)	1.05 (1.04–1.06)	
<b>Ethnicity</b>			
White	2008 (54.9)	1.00 (0.99–1.01)	<0.0001
Black	630 (17.2)	1.07 (1.05–1.09)	
Hispanic	913 (25.0)	1.04 (1.02–1.05)	
Others	109 (3.0)	1.05 (1.01–1.09)	
<b>Monthly income (\$)</b>			
≤20,000	1078 (29.5)	1.01 (1.00–1.03)	<0.0001
>20,000	2582 (70.6)	1.03 (1.02–1.03)	
<b>Smoking status</b>			
Current smoker	828 (22.6)	1.05 (1.03–1.06)	0.3777
Ex-smoker	973 (26.6)	0.97 (0.96–0.98)	
Never smoked	1859 (50.8)	1.04 (1.03–1.05)	
<b>Alcohol drinking</b>			
Drinker	2513 (68.7)	1.03 (1.02–1.04)	0.0018
Non-drinker	1147 (31.3)	1.01 (0.99–1.02)	
<b>History of diabetes</b>			
Yes	399 (10.9)	0.94 (0.92–0.96)	<0.0001
No	3261 (89.1)	1.03 (1.02–1.04)	
<b>BMI (kg/m<sup>2</sup>)</b>			
Underweight (<18.5)	63 (1.7)	1.09 (1.01–1.18)	0.0004
Normal weight (18.5–24.9)	1095 (29.9)	1.04 (1.03–1.06)	
Overweight (25–29.9)	1372 (37.5)	1.01 (1.00–1.02)	
Obese (≥30)	1130 (30.9)	1.01 (1.00–1.02)	
<b>Homocysteine, serum (μmol/L)</b>			
Q1 (<6.36)	788 (21.5)	1.10 (1.08–1.12)	<0.0001
Q2 (6.37–7.88)	942 (25.7)	1.05 (1.04–1.07)	
Q3 (7.89–10.00)	989 (27.0)	1.01 (0.99–1.02)	
Q4 (≥10.01)	941 (25.7)	0.95 (0.94–0.96)	
<b>Folate, serum (ng/mL)</b>			
Q1 (<9.1)	959 (26.2)	1.04 (1.03–1.06)	<0.0001
Q2 (9.1–12.8)	951 (26.0)	1.03 (1.01–1.04)	
Q3 (12.9–18.2)	954 (26.1)	1.03 (1.01–1.05)	
Q4 (≥18.3)	796 (21.8)	0.98 (0.96–1.00)	
<b>Dietary eicosapentaenoic (g)</b>			
Q1 (<0.001)	1056 (28.9)	1.02 (1.01–1.04)	0.3258
Q2 (0.001–0.003)	571 (15.6)	1.00 (0.98–1.02)	
Q3 (0.004–0.014)	1078 (29.5)	1.03 (1.02–1.05)	
Q4 (≥0.015)	955 (26.1)	1.03 (1.01–1.04)	

**Table 1** continued

	<i>N</i> (%)	Mean (95 % CI)	<i>p</i> value
Dietary docosahexaenoic (g)			
Q1 (<0.001)	732 (20.0)	1.03 (1.01–1.05)	0.7977
Q2 (0.001–0.021)	1011 (27.6)	1.01 (1.00–1.03)	
Q3 (0.022–0.059)	972 (26.6)	1.03 (1.01–1.05)	
Q4 ( $\geq$ 0.060)	945 (25.8)	1.02 (1.01–1.04)	

**Table 2** Pearson's correlation structure of serum carotenoid levels

	Alpha-carotene	Beta-carotene ( <i>trans</i> + <i>cis</i> )	Beta-cryptoxanthin	Combined lutein/zeaxanthin	<i>Trans</i> -lycopene
Alpha-carotene	1				
Beta-carotene ( <i>trans</i> + <i>cis</i> )	0.65	1			
Beta-cryptoxanthin	0.34	0.41	1		
Combined lutein/zeaxanthin	0.39	0.42	0.47	1	
<i>Trans</i> -lycopene	0.13	0.14	0.16	0.20	1

quartiles based on their distribution. Omega-3 fatty acids were obtained from two diets containing eicosapentaenoic acid and docosahexaenoic acid, in which these two dietary intakes were also categorized into the quartiles.

### Statistical analysis

We applied weighted estimates of the population parameters based on the NHANES Analytic and Reporting Guidelines. All the statistical analyses were performed using the PROC SURVEY procedures in SAS 9.2 (SAS Institute, Cary, NC, USA) to account for the complex sampling scheme. All the tests were two-sided, with the level of statistical significance set to  $\alpha = 0.05$ .

The mean telomere length in leukocytes and its 95 % confidence interval (CI) were computed according to the characteristics of the study participants. The adjusted mean and 95 % CI of the telomere length were also calculated by adjusting for age, gender, ethnicity, monthly income, smoking status, alcohol, BMI, and history of diabetes.

Each carotenoid level was log-transformed and treated as a continuous variable. Risk analysis was conducted using a linear regression model by providing the percent change  $[(e^{(\ln 2 * \beta)} - 1) * 100 \text{ %}]$  in the telomere length for a doubling of the blood carotenoid levels, with the estimated 95 % CI as  $(e^{(\ln 2 * (\beta \pm 1.96 * SE))} - 1) * 100 \text{ %}$ , where  $\beta$  is the estimated regression coefficient and SE is standard error. Additionally, the serum carotenoid level was categorized into quartiles, and logistic regression was used to assess the percent change in leukocyte telomere length for each quartile of the carotenoid distribution compared with the lowest quartile of blood carotenoid. For each analysis, age, gender, ethnicity, income, smoking, drinking, the presence of diabetes, BMI, serum homocysteine and folate levels, dietary eicosapentaenoic acid and docosahexaenoic intakes, and

smoking–carotenoid interaction were adjusted as potential confounders.

### Results

Table 1 shows the mean leukocyte telomere length according to the study characteristics. The mean (95 % CI) telomere length had a 1.05 (95 % CI 1.03–1.07) *T/S* ratio for the study population. The telomere length differed significantly by age, gender, ethnicity, income, alcohol drinking, BMI, and history of diabetes, and the serum homocysteine and folate levels were more likely to be low in subjects who were older, male, non-drinkers, white, and overweight (BMI of 25–29.9 kg/m<sup>2</sup>) and had a low income, diabetes, and high serum homocysteine or folate levels. However, the data did not show a significant difference in smoking status, and dietary eicosapentaenoic and docosahexaenoic intake.

Table 2 shows the correlation structure of serum carotenoid levels. The carotenoid levels were significantly correlated with each other, and the coefficients were ranged from 0.13 to 0.65.

Table 3 shows the estimated beta coefficients (SE) and percent changes in leukocyte telomere length (*T/S* ratio) by blood carotenoid levels. There was a significant association between provitamin A carotenoids (i.e., alpha-carotene, beta-carotene (*trans* + *cis*), and beta-cryptoxanthin) and telomere length, whereas there was no association between non-vitamin A carotenoids (i.e., combined lutein/zeaxanthin and *trans*-lycopene) and telomere length. For continuous carotenoid levels, a doubling of blood alpha-carotene, beta-carotene (*trans* + *cis*), and beta-cryptoxanthin was associated with 1.76 % ( $\beta = 0.017$ ; SE = 0.007), 2.22 % ( $\beta = 0.022$ ; SE = 0.008), and 2.02 % ( $\beta = 0.020$ ;

**Table 3** Beta coefficient (SE) and percent change (%) in leukocyte telomere length (T/S ratio) by blood carotenoid levels

	N	Model 1			Model 2			Model 3					
		$\beta$	(SE)	% change	p value	$\beta$	(SE)	% change	p value	$\beta$	(SE)	% change	p value
Alpha-carotene ( $\mu\text{g/dL}$ )													
Per doubling of alpha-carotene		0.017	(0.006)	1.75	0.0108	0.018	0.007	1.84	0.0148	0.017	(0.007)	1.76	0.0211
Quartile of alpha-carotene	946	Reference		Reference		Reference		Reference		Reference		Reference	
Q1 ( $\leq 1.4$ )	876	0.019	(0.012)	1.87	0.1331	0.022	(0.015)	2.23	0.1604	0.019	(0.015)	1.91	0.2264
Q2 (1.5–2.7)	922	0.043	(0.026)	4.37	0.1162	0.029	(0.028)	2.91	0.3264	0.025	(0.027)	2.54	0.3710
Q3 (2.8–5.1)	914	0.059	(0.024)	6.04	0.0287	0.065	(0.025)	6.73	0.0217	0.060	(0.024)	6.14	0.0253
Q4 ( $\geq 5.2$ )													
Beta-carotene ( <i>trans</i> + <i>cis</i> ) ( $\mu\text{g/dL}$ )													
Per doubling of beta-carotene		0.018	(0.007)	1.79	0.0307	0.025	(0.008)	2.51	0.0071	0.022	(0.008)	2.22	0.0124
Quartile of beta-carotene	902	Reference		Reference		Reference		Reference		Reference		Reference	
Q1 ( $\leq 7.9$ )	916	0.025	(0.012)	2.57	0.0495	0.030	(0.015)	3.04	0.056	0.024	(0.025)	2.46	0.3503
Q2 (8.0–13.8)	928	0.037	(0.018)	3.73	0.0578	0.029	(0.020)	2.86	0.1517	0.010	(0.018)	1.01	0.5932
Q3 (13.9–24.4)	912	0.071	(0.023)	7.34	0.0085	0.086	(0.023)	8.90	0.0014	0.076	(0.029)	7.94	0.0183
Q4 ( $\geq 24.5$ )													
Beta-cryptoxanthin ( $\mu\text{g/dL}$ )													
Per doubling of beta-cryptoxanthin		0.022	(0.009)	2.23	0.0212	0.025	(0.007)	2.54	0.0022	0.020	(0.006)	2.02	0.0062
Quartile of beta-cryptoxanthin	901	Reference		Reference		Reference		Reference		Reference		Reference	
Q1 ( $\leq 4.9$ )	900	0.020	(0.013)	1.99	0.1545	-0.001	(0.013)	-0.15	0.9127	-0.003	(0.015)	-0.29	0.8436
Q2 (5–7.9)	921	0.044	(0.023)	4.52	0.0731	0.047	(0.022)	4.85	0.0475	0.045	(0.022)	4.56	0.0639
Q3 (8–13.2)	921	0.053	(0.022)	5.42	0.0291	0.052	(0.018)	5.36	0.0127	0.049	(0.017)	5.06	0.0120
Q4 ( $\geq 13.3$ )													
Combined lutein/zeaxanthin ( $\mu\text{g/dL}$ )													
Per doubling of lutein/zeaxanthin		0.020	(0.010)	2.05	0.0557	0.021	(0.011)	2.13	0.0801	0.014	(0.007)	1.37	0.0856
Quartile of lutein/zeaxanthin	893	Reference		Reference		Reference		Reference		Reference		Reference	
Q1 ( $\leq 10.2$ )	944	0.021	(0.015)	2.10	0.1794	-0.001	(0.017)	-0.08	0.9605	-0.004	(0.016)	-0.42	0.8014
Q2 (10.3–14.4)	907	0.019	(0.020)	1.95	0.3581	0.016	(0.024)	1.64	0.5156	0.011	(0.024)	1.09	0.6521
Q3 (14.5–20.4)	912	0.027	(0.019)	2.79	0.1679	0.026	(0.017)	2.61	0.1575	0.019	(0.014)	1.88	0.2176
Q4 ( $\geq 20.5$ )													
<i>Trans</i> -lycopene ( $\mu\text{g/dL}$ )													
Per doubling of <i>trans</i> -lycopene		0.016	(0.008)	1.59	0.0593	0.016	(0.011)	1.60	0.1826	0.008	(0.007)	0.82	0.2888

Table 3 continued

Quartile of <i>trans</i> -lycopene	N	Model 1			Model 2			Model 3					
		$\beta$	(SE)	% change	p value	$\beta$	(SE)	% change	p value	$\beta$	(SE)	% change	p value
Q1 ( $\leq 14.1$ )	880	Reference	Reference	Reference	Reference	Reference	Reference	Reference	Reference	Reference	Reference	Reference	Reference
Q2 (14.2–20.7)	917	0.010	(0.014)	0.96	0.5048	-0.006	(0.016)	-0.56	0.7338	-0.006	(0.016)	-0.64	0.6954
Q3 (20.8–28.6)	910	0.002	(0.011)	0.24	0.8203	-0.028	(0.015)	-2.72	0.0953	-0.027	(0.016)	-2.70	0.1004
Q4 ( $\geq 28.7$ )	949	0.040	(0.014)	4.13	0.0119	0.024	(0.016)	2.45	0.1514	0.024	(0.015)	2.47	0.1271

Model 1 was adjusted for age, gender, and ethnicity

Model 2 was further adjusted for family income, smoking status, alcohol drinking, BMI, the presence of diabetes, and interactions with smoking \* serum carotene levels

Model 3 was further adjusted for dietary omega 3 (eicosapentaenoic and docosahexaenoic) and serum levels of folate and homocysteine

SE = 0.006) longer telomeres, respectively. Compared with the lowest carotenoid quartiles (Q1), the fully adjusted percent changes for telomere length in the highest carotenoid quartiles (Q4) increased by 6.14 % ( $\beta = 0.060$ ; SE = 0.024) for alpha-carotene, 7.94 % ( $\beta = 0.076$ ; SE = 0.029) for beta-carotene (*trans* + *cis*), and 5.06 % ( $\beta = 0.049$ ; SE = 0.017) for beta-cryptoxanthin.

## Discussion

We found that increased levels of blood carotenoid were significantly associated with longer leukocyte telomeres in US adults. Specifically, a doubling of blood alpha-carotene, beta-carotene (*trans* + *cis*), and beta-cryptoxanthin levels was associated with approximately 2 % longer telomeres. Compared with the lowest carotenoid quartile of alpha-carotene, beta-carotene (*trans* + *cis*), and beta-cryptoxanthin, the telomere length for adults with the highest quartiles was significantly increased, by 5–8 %. Our results support a link between antioxidant status and telomere length and suggest that a high intake of carotenoid-rich foods may play a role in protecting telomeres and regulating telomere length.

Telomeres, the specialized terminal regions of chromosomes, do not encode any proteins; however, they protect the chromosome from damage during cell division [1]. Telomeres are essential for regulating the life span of human cells, and their progressive shortening has been implicated in cellular senescence and apoptosis [2]. Although telomere length is highly heterogeneous and inherited [17], it has been proposed as a biomarker for aging, health, and survival [18]. Accumulating evidence has indicated that shorter telomeres are associated with biological age, life span, and increased risk of aging-related diseases and stressful life circumstances [16, 19–22]. Increased oxidative stress has been considered a key player in the mechanism of telomere shortening associated with these conditions [4, 23]. In telomeres, guanine is highly sensitive to damage by oxidative stress. Furthermore, the production of reactive oxygen species from oxidative stress induces modified bases (mainly 8-oxoG) and single-strand breaks that interfere with the replication fork at telomeric repeats, thus leading to an increase in the rate of telomere shortening by oxidative stress.

Based on this knowledge, antioxidants may play an important role in protecting against cellular damage, slowing the aging process, and preventing diseases driven by oxidative stress. A series of studies demonstrated the possible role of dietary antioxidants on telomere length [7, 8]. A recent study of García-Calzón et al. [24] suggested that dietary total antioxidant capacity was associated with leukocyte telomere length. Notably, dietary patterns with antioxidant properties, such as Mediterranean dietary intake and

a high consumption of vegetables and fruits, and omega-3 fatty acids, have been linked with telomere length, emphasizing its protective role on telomere length [7, 25–27].

Only one recent study has shown a beneficial effect of carotenoids, as a potential antioxidant, on maintaining telomere length [12]. Sen et al. [12] investigated the association between plasma antioxidant levels and leukocyte telomere length in 786 elderly adults. A strong and significant effect of combined lutein/zeaxanthin on longer telomeres ( $\beta = 0.120$ ,  $p$  value  $<0.01$ ) was observed, whereas no other carotenoids were associated with telomere length. However, we observed that the serum levels of provitamin A carotenoids, including alpha-carotene, beta-carotene (*trans* + *cis*), and beta-cryptoxanthin, were significantly associated with longer telomeres, whereas non-vitamin A carotenoids, including combined lutein/zeaxanthin and *trans*-lycopene, did not acquire statistical significance. Such a discrepancy may arise from the use of different methodologies, such as the size of the study population, age distribution, and confounding variables. Additional, carefully designed studies are needed to clarify the effect of carotenoid on telomeres.

Despite the potential controversy, the role of carotenoid in the protection of telomere loss is biologically plausible. Oxygen is essential to life, but too much oxygen is potentially harmful. Although the human body produces oxygen free radicals and other reactive oxygen species as by-products of various metabolic processes, overproduction induces oxidative damage to relevant molecules (DNA, proteins, and lipids), eventually leading to an increased risk of many chronic diseases and aging [28, 29]. Antioxidants have attracted attention as an efficient tool in counteracting oxidative stress [30, 31]. Carotenoids are particularly promising antioxidants, because they are capable of exerting antioxidant protection by scavenging singlet molecular oxygen and peroxy radicals [10, 32]. Several human studies have supported carotenoid protection against oxidation and oxidative stress-induced, age-related conditions [33, 34]. However, although carotenoids are well-known antioxidants due to their health benefits, their effect on DNA damage appears to differ for the pro- and non-vitamin A carotenoids. Results from cell culture, animal experiments, and human trials show that non-vitamin A carotenoids are almost invariably reported to protect against DNA damage [35]. In contrast, provitamin A carotenoids have complicated effects, sometimes protecting and sometimes increasing DNA damage [35, 36]. At high concentrations or at a high partial pressure of oxygen, the carotenoids, mostly beta-carotene, may have pro-oxidant properties rather than playing a protective antioxidant role. Thus, subsequent studies are required to identify whether there are different effects on protecting the telomere length by specific types of carotenoids.

To our knowledge, this is the first study to report longer telomeres in leukocyte associated with blood carotenoid levels using a large-scale, high-power, and strict quality control procedures survey of the NHANES data. However, several limitations should be considered. First, the cross-sectional design of this study does not permit a causal inference for the observed association. Second, although blood carotenoid level is commonly used in nutrition epidemiologic studies, it is not an accurate reflection of life time exposure. Finally, because higher serum carotenoid levels are considered to be a marker of a healthy lifestyle [37], their association with the leukocyte telomere length may solely reflect the protective role of a healthy lifestyle on biological aging. Despite making adjustments for lifestyle-related variables (i.e., smoking, BMI, and alcohol use), we cannot exclude the possibility of residual confounding effects by unmeasured confounders.

In conclusion, we found a significant, positive association between leukocyte telomere shortening and blood carotenoid levels, especially for alpha-carotene, beta-carotene (*trans* + *cis*), beta-cryptoxanthin, and *trans*-lycopene, in US adults. Although the findings need to be confirmed, they suggest that carotenoids have a protective effect on telomere loss and that a high intake of these carotenoids may potentially prevent or delay the aging process and age-related diseases.

**Acknowledgments** This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (Grant Numbers: 2015R1A1A3A04000923, 2015R1D1A1A01059048).

**Compliance with ethical standards**

**Conflict of interest** None declared.

## References

1. Blackburn EH (1991) Structure and function of telomeres. *Nature* 350:569–573. doi:10.1038/350569a0
2. Blackburn EH (2005) Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. *FEBS Lett* 579:859–862. doi:10.1016/j.febslet.2004.11.036
3. Fyhrquist F, Saijonmaa O, Strandberg T (2013) The roles of senescence and telomere shortening in cardiovascular disease. *Nat Rev Cardiol* 10:274–283. doi:10.1038/nrcardio.2013.30
4. von Zglinicki T (2002) Oxidative stress shortens telomeres. *Trends Biochem Sci* 27:339–344
5. Adelfalk C, Lorenz M, Serra V, von Zglinicki T, Hirsch-Kauffmann M, Schweiger M (2001) Accelerated telomere shortening in Fanconi anemia fibroblasts—a longitudinal study. *FEBS Lett* 506:22–26
6. Lorenz M, Saretzki G, Sitte N, Metzkwow S, von Zglinicki T (2001) BJ fibroblasts display high antioxidant capacity and slow telomere shortening independent of hTERT transfection. *Free Radic Biol Med* 31:824–831

7. Tiainen AM, Männistö S, Blomstedt PA, Moltchanova E, Perälä MM, Kaartinen NE, Kajantie E, Kananen L, Hovatta I, Eriksson JG (2012) Leukocyte telomere length and its relation to food and nutrient intake in an elderly population. *Eur J Clin Nutr* 66:1290–1294. doi:10.1038/ejcn.2012.143
8. Xu Q, Parks CG, DeRoo LA, Cawthon RM, Sandler DP, Chen H (2009) Multivitamin use and telomere length in women. *Am J Clin Nutr* 89:1857–1863. doi:10.3945/ajcn.2008.26986
9. Cooper DA (2004) Carotenoids in health and disease: recent scientific evaluations, research recommendations and the consumer. *J Nutr* 134:221S–224S
10. Krinsky NI, Johnson EJ (2005) Carotenoid actions and their relation to health and disease. *Mol Aspects Med* 26:459–516. doi:10.1016/j.mam.2005.10.001
11. Min JY, Min KB (2014) Serum lycopene, lutein and zeaxanthin, and the risk of Alzheimer's disease mortality in older adults. *Dement Geriatr Cogn Disord* 37:246–256. doi:10.1159/000356486
12. Sen A, Marsche G, Freudenberger P, Schallert M, Toeglhofer AM, Nagl C, Schmidt R, Launer LJ, Schmidt H (2014) Association between higher plasma lutein, zeaxanthin, and vitamin C concentrations and longer telomere length: results of the Austrian Stroke Prevention Study. *J Am Geriatr Soc* 62:222–229. doi:10.1111/jgs.12644
13. National Center for Environmental Health (2007) Centers for Disease Control and Prevention Web site. Laboratory procedure manual: fat soluble micronutrients. National Center for Environmental Health. [http://www.cdc.gov/nchs/data/nhanes/nhanes\\_99\\_00/lab06\\_met\\_aecar.pdf](http://www.cdc.gov/nchs/data/nhanes/nhanes_99_00/lab06_met_aecar.pdf). Accessed 02 April 2015
14. Cawthon RM (2002) Telomere measurement by quantitative PCR. *Nucleic Acids Res* 30:e47
15. Lin J, Epel E, Cheon J, Kroenke C, Sinclair E, Bigos M, Wolkowitz O, Mellon S, Blackburn E (2010) Analyses and comparisons of telomerase activity and telomere length in human T and B cells: insights for epidemiology of telomere maintenance. *J Immunol Methods* 352:71–80. doi:10.1016/j.jim.2009.09.012
16. Needham BL, Adler N, Gregorich S, Rehkopf D, Lin J, Blackburn EH, Epel ES (2013) Socioeconomic status, health behavior, and leukocyte telomere length in the National Health and Nutrition Examination Survey, 1999–2002. *Soc Sci Med* 85:1–8. doi:10.1016/j.socscimed.2013.02.023
17. Slagboom PE, Droog S, Boomsma DI (1994) Genetic determination of telomere size in humans: a twin study of three age groups. *Am J Hum Genet* 55:876–882
18. Jiang H, Schiffer E, Song Z, Wang J, Zurbig P, Thedieck K, Moes S, Bantel H, Saal N, Jantos J, Brecht M, Jenö P, Hall MN, Hager K, Manns MP, Hecker H, Ganser A, Dohner K, Bartke A, Meissner C, Mischak H, Ju Z, Rudolph KL (2008) Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. *Proc Natl Acad Sci USA* 105:11299–11304. doi:10.1073/pnas.0801457105
19. Aubert G, Lansdorp PM (2008) Telomeres and aging. *Physiol Rev* 88:557–579. doi:10.1152/physrev.00026.2007
20. Cawthon RM, Smith KR, O'Brien E, Sivatchenko A, Kerber RA (2003) Association between telomere length in blood and mortality in people aged 60 years or older. *Lancet* 361:393–395. doi:10.1016/s0140-6736(03)12384-7
21. Shammass MA (2011) Telomeres, lifestyle, cancer, and aging. *Curr Opin Clin Nutr Metab Care* 14:28–34. doi:10.1097/MCO.0b013e32834121b1
22. Monaghan P, Haussmann MF (2006) Do telomere dynamics link lifestyle and lifespan? *Trends Ecol Evol* 21:47–53. doi:10.1016/j.tree.2005.11.007
23. Babizhayev MA, Savel'yeva EL, Moskvina SN, Yegorov YE (2011) Telomere length is a biomarker of cumulative oxidative stress, biologic age, and an independent predictor of survival and therapeutic treatment requirement associated with smoking behavior. *Am J Ther* 18:e209–e226. doi:10.1097/MJT.0b013e3181cf8ebb
24. García-Calzón S, Molerés A, Martínez-González MA, Martínez JA, Zalba G, Martí A, GENOI Members (2015) Dietary total antioxidant capacity is associated with leukocyte telomere length in a children and adolescent population. *Clin Nutr* 34:694–699. doi:10.1016/j.clnu.2014.07.015
25. Crous-Bou M, Fung TT, Prescott J, Julin B, Du M, Sun Q, Rexrode KM, Hu FB, De Vivo I (2014) Mediterranean diet and telomere length in Nurses' Health Study: population based cohort study. *Br Med J* 349:g6674. doi:10.1136/bmj.g6674
26. Kiecolt-Glaser JK, Epel ES, Belury MA, Andridge R, Lin J, Glaser R, Malarkey WB, Hwang BS, Blackburn E (2013) Omega-3 fatty acids, oxidative stress, and leukocyte telomere length: a randomized controlled trial. *Brain Behav Immun* 28:16–24. doi:10.1016/j.bbi.2012.09.004
27. Marcon F, Siniscalchi E, Crebelli R, Saieva C, Sera F, Fortini P, Simonelli V, Palli D (2012) Diet-related telomere shortening and chromosome stability. *Mutagenesis* 27:49–57. doi:10.1093/mutage/ger056
28. Berlett BS, Stadtman ER (1997) Protein oxidation in aging, disease, and oxidative stress. *J Biol Chem* 272:20313–20316
29. Mariani E, Polidori MC, Cherubini A, Mecocci P (2005) Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. *J Chromatogr B Analyt Technol Biomed Life Sci* 827:65–75. doi:10.1016/j.jchromb.2005.04.023
30. Urso ML, Clarkson PM (2003) Oxidative stress, exercise, and antioxidant supplementation. *Toxicology* 189:41–54
31. Uttara B, Singh AV, Zamboni P, Mahajan RT (2009) Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. *Curr Neuropharmacol* 7:65–74. doi:10.2174/157015909787602823
32. Stahl W, Sies H (2005) Bioactivity and protective effects of natural carotenoids. *Biochim Biophys Acta* 1740:101–107. doi:10.1016/j.bbadis.2004.12.006
33. Stahl W, Sies H (2003) Antioxidant activity of carotenoids. *Mol Aspects Med* 24:345–351
34. Riccioni G (2009) Carotenoids and cardiovascular disease. *Curr Atheroscler Rep* 11:434–439
35. Azqueta A, Collins AR (2012) Carotenoids and DNA damage. *Mutat Res* 733:4–13. doi:10.1016/j.mrfmmm.2012.03.005
36. Young AJ, Lowe GM (2001) Antioxidant and prooxidant properties of carotenoids. *Arch Biochem Biophys* 385:20–27
37. Thyagarajan B, Meyer KA, Smith LJ, Beckett WS, Williams OD, Gross MD, Jr Jacobs DR (2011) Serum carotenoid concentrations predict lung function evolution in young adults: the Coronary Artery Risk Development in Young Adults (CARDIA) study. *Am J Clin Nutr* 94:1211–1218. doi:10.3945/ajcn.111.019067